Imugene Ltd (OTC:IUGNF) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertible notes (New Notes) Terms changed: convertible Buyers: CVI Investments, Inc. | Nov 2, 2026 | |
| Convertible notes (TAR Notes) Terms changed: convertible Buyers: CVI Investments, Inc. | Nov 2, 2026 | |
| Private placement of fully paid ordinary shares Closed: A$0.095 a share | Sep 1, 2026 | |
| Convertible notes (TAR Notes) and warrants Closed: A$2.1M raised · Warrants at A$0.0664 for 60 months Buyers: CVI Investments, Inc. ($2,100,000 worth of TAR Notes and 25,301,205 New Warrants) Use of proceeds: Fund Cohort 2 and new Cohort 3 (BTKi) of its Phase 1b trial, plus general administrative and working capital | Aug 27, 2026 | US$1.49M |
| Private placement of new shares with attaching options Announced: A$22.5M · A$0.33 a share · Warrants at A$0.43 Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26 | Jul 16, 2025 | US$14.67M |
| Share purchase plan of new shares with attaching options Announced: A$15M · A$0.33 a share · Warrants at A$0.43 Use of proceeds: Primarily to fund the azer-cel program through to initiating a pivotal clinical trial in CY26 | Jul 16, 2025 | US$9.78M |